China has at least five COVID-19 vaccine candidates running late stage clinical trials across more than a dozen countries.

Sino Biopharmaceutical Ltd., a pharmaceutical conglomerate, bought a 15 per cent stake in Sinovac for an investment of USD 500 million.

The funds will allow the company to “improve our vaccine sales capabilities, expand in Asia markets, develop and access new technologies, and most importantly, accelerate our efforts to help combat the global pandemic,” Sinovac CEO Yin Weidong said in a statement.…

This news comes via ChinaPulse.com, which delivers news, data, analysis, and insights on Chinese business, travel, finance, health, military, investment, and technology.